Real world experience with teriflunomide in multiple sclerosis: the TER-Italy study.
Sebastiano BucelloPietro AnnovazziPaolo RagoneseMarta AltieriValeria BarcellaRoberto BergamaschiAlessia BianchiGiovanna BorrielloMaria Chiara BuscarinuGraziella CallariMarco CapobiancoFioravante CaponePaola CavallaRosella CavarrettaAntonio CorteseGiovanna De LucaMassimiliano Di FilippoVincenzo DattolaRoberta FantozziElisabetta FerraroMaria Maddalena FilippiClaudio GasperiniLuigi Maria Edoardo GrimaldiDoriana LandiMarianna Lo ReGiulia MallucciPaolo ManganottiGirolama Alessandra MarfiaMassimiliano MirabellaPaola PeriniMarco PisaSabrina RealmutoMargherita RussoValentina TomassiniValentina Liliana Adriana Torri-ClericiMauro ZaffaroniCristina ZulianiSofia ZywickiMassimo FilippiLuca ProsperiniPublished in: Journal of neurology (2021)
Our study suggests a place-in-therapy for teriflunomide in naïve patients with mild disability level or in those who switched their initial treatment for poor tolerability. Adverse events related with teriflunomide were consistent with literature data, without any new safety concern.